SAB Biotherapeutics (NASDAQ: SABS) posts new corporate presentation

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. reported that on January 12, 2026 it posted an updated corporate presentation on its official website. The presentation, dated January 12, 2026 and referenced as Exhibit 99.1, is intended for investors and other stakeholders seeking an overview of the company and its plans. The disclosure notes that this presentation is being furnished rather than filed under securities laws, meaning it is not automatically incorporated into other regulatory documents unless specifically referenced.

false00018332140001833214sabs:WarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember2026-01-122026-01-120001833214us-gaap:CommonStockMember2026-01-122026-01-1200018332142026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

SAB BIOTHERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39871	85-3899721
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
777 W 41st St Suite 401
Miami Beach, Florida				33140
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 305 845-2813

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value per share		SABS		The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of Common Stock		SABSW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, SAB Biotherapeutics, Inc. (the “Company”) posted an updated corporate presentation set forth as Exhibit 99.1 herein on the Company’s official website. The Company undertakes no duty or obligation to update or revise the information contained in this presentation, although it may do so from time to time. Any such updates may be made through the Investor Relations page of the Company’s website, the filing of other reports or documents with the U.S. Securities and Exchange Commission, press releases, or other public disclosure. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall they be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Corporate Presentation dated January 12, 2026
104	Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SAB Biotherapeutics, Inc.
Date:	January 12, 2026	By:	/s/ Samuel J. Reich
			Samuel J. Reich

FAQ

What did SAB Biotherapeutics (SABS) disclose in this report?

SAB Biotherapeutics disclosed that it posted an updated corporate presentation on January 12, 2026 on its official website, furnished as Exhibit 99.1.

Where can investors find the new SAB Biotherapeutics (SABS) corporate presentation?

Investors can access the updated corporate presentation through the Investor Relations page of SAB Biotherapeutics’ official website, as referenced in the disclosure.

What is the date of the new SAB Biotherapeutics (SABS) corporate presentation?

The new SAB Biotherapeutics corporate presentation is dated January 12, 2026, as indicated in the exhibit description.

Is the SAB Biotherapeutics (SABS) presentation considered filed with the SEC?

No. The company states that the information in Item 7.01, including Exhibit 99.1, is being furnished and not filed under the Exchange Act or Securities Act unless later specifically incorporated by reference.

Will SAB Biotherapeutics (SABS) update this corporate presentation in the future?

The company notes it has no duty or obligation to update or revise the presentation, although it may do so from time to time through its website or other public disclosures.

Which securities of SAB Biotherapeutics are listed on Nasdaq?

The disclosure lists common stock under the symbol SABS and warrants, each exercisable for one share of common stock, under the symbol SABSW on The Nasdaq Stock Market LLC.